Ivonescimab for metastatic lobular breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called ivonescimab for people with a specific type of breast cancer called invasive lobular carcinoma that has spread and is no longer responding to hormone therapy or is triple-negative. The goal is to see if it can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have invasive lobular carcinoma confirmed by a biopsy showing no E-cadherin.
- Your cancer must be hormone receptor-positive (and resistant to at least one hormone therapy) or triple-negative, and HER2-negative.
- You must be willing to have a biopsy if the tumor can be safely reached.
- You must have a good performance status (able to do daily activities).
- You must have measurable disease or a lytic bone lesion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
This trial tests whether giving a new immunotherapy drug (ivonescimab) together with standard chemotherapy before surgery can help shrink triple-negative breast cancer and improve outcomes.
This trial tests an immunotherapy drug for people with stage 3 lung cancer that hasn't been treated yet. It's for those whose tumors don't have certain genetic changes and who have not had prior cancer treatment.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Hear when a new Metastatic Endocrine Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.